Latest News

California will make low-cost insulin, Gov. Newsom says


 

California Gov. Gavin Newsom says the state government will manufacture its own low-cost insulin to make the drug more affordable for residents.

On July 7, he said he had just signed a state budget that includes $50 million for development of the insulin and another $50 million for a place to make it.

“Nothing, nothing epitomizes market failures more than the cost of insulin,” Gov. Newsom said in a video posted on the governor’s Twitter page. He noted that many Americans have out-of-pocket costs ranging from $300 to $500 per month for insulin, which is used to treat diabetes.

“In California, we know people should not go into debt to receive lifesaving medication,” he said.

Gov. Newsom said that when he first took office, he signed an executive order to launch California’s own prescription drug system and that the insulin initiative is the first step toward making that happen.

People who take insulin have long complained about its high price. A November 2021 report from The Lancet said 25% of the insulin patients in the United States struggle to pay for it.

The cost of insulin for patients with insurance ranges from $334 to $1,000 a month, ABC News said, citing the Kaiser Family Foundation.

Legislation in Congress would bring down the cost of insulin if passed, with one bill capping costs at $35 per month for patients with health insurance. But The Hill reported that some Republicans oppose the legislation because it would interfere with free markets and raise costs for drug companies.

The CDC says 37.3 million people in the United States – about 11.3% of the population – have diabetes, with 8.5 million of them undiagnosed.

A version of this article first appeared on WebMD.com.

Recommended Reading

Antidiabetes drug costs keep patients away
Journal of Clinical Outcomes Management
‘Remission is possible’ for patients with type 2 diabetes
Journal of Clinical Outcomes Management
New guideline for in-hospital care of diabetes says use CGMs
Journal of Clinical Outcomes Management
SGLT2 inhibitors cut AFib risk in real-word analysis
Journal of Clinical Outcomes Management
Exercise of any type boosts type 1 diabetes time in range
Journal of Clinical Outcomes Management
Diabetes tied to risk of long COVID, too
Journal of Clinical Outcomes Management
Heart failure: Medicare cost sharing may put quadruple therapy out of reach
Journal of Clinical Outcomes Management
What’s the best time of day to exercise? It depends on your goals
Journal of Clinical Outcomes Management
Cardiologists concerned for patient safety after abortion ruling
Journal of Clinical Outcomes Management
Cancer may increase risk of type 2 diabetes
Journal of Clinical Outcomes Management